ELHT Evidence Hub
  • Home
  • Meet the Team
  • Library Facilities
  • Library News
  • FAQS
Picture

Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis

29/10/2021

0 Comments

 
Author(s) Ali Z.; Al-Janabi A.; Warren R.B.; Matthews R.
Source Expert Review of Clinical Immunology; 2021; vol. 17 (no. 10); p. 1073-1081
Language English
Publication Date 2021
DOI 10.1080/1744666X.2021.1967748
ISSN 1744-666X
Database EMBASE
​Abstract
Introduction: Interleukin (IL)-17 is critical in the pathogenesis of psoriasis and psoriatic arthritis (PsA) with most data suggesting that IL-17A alone was the key cytokine. However, in vitro and in vivo studies have suggested dual blockade of IL-17A and IL-17 F may be more effective than IL-17 A blockade alone. Bimekizumab is the first human monoclonal antibody to exert simultaneous specific inhibition of IL-17A and IL-17 F, and has been studied in several phase II/III trials for psoriasis and PsA. Areas covered: Bimekizumab is not currently licensed for use. A literature search identified clinical trials examining the efficacy and safety of bimekizumab for psoriasis and PsA, and these were critically appraised. Expert opinion: Clinical trials of bimekizumab have been promising, demonstrating a rapid onset of response and superior efficacy compared to three currently licensed biologics: secukinumab, ustekinumab, and adalimumab. Bimekizumab maintains a high level of efficacy with maintenance dosing intervals of 8 weeks, compared with 4 weeks for currently licensed IL-17A antagonists. No unexpected adverse events have been identified, although mild-to-moderate fungal infections occur in approximately 10%. Studies over longer time periods involving additional active comparators would be valuable in further defining the role of bimekizumab amongst currently available treatments.
  • Request full text article from the library
0 Comments



Leave a Reply.

    The following databases were searched:
    EMBASE,  MEDLINE, PsycINFO, BNI, CINAHL, 
    to find  ELHT staff publications

    Specialties

    All
    ANAESTHETICS
    CAMHS
    CARDIOLOGY
    COVID 19
    DEMENTIA
    DERMATOLOGY
    DIABETES
    DIETETICS
    EMERGENCY CARE
    ENDOCRINOLOGY
    EVIDENCE BASED MEDICINE
    GYNAECOLOGY
    HAEMATOLOGY
    MAXILLOFACIAL
    NEONATOLOGY
    NEUROLOGY
    NURSING
    OBSTETRICS
    ONCOLOGY
    ORTHOPAEDICS
    PAEDIATRICS
    PHARMACY
    PHYSIOTHERAPY
    RADIOLOGY
    RESPIRATORY
    RHEUMATOLOGY
    STROKE
    SURGERY
    UROLOGY
    VASCULAR SURGERY

    RSS Feed

    Archives

    May 2022
    April 2022
    March 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    December 2020
    November 2020
    October 2020
    September 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019

Learning Centre Library
Royal Blackburn Teaching Hospital
01254 734312 or Ext 84312
library.blackburn@elht.nhs.uk
​Find us
​​Mackenzie Library
Burnley General Teaching Hospital
01282 803114 or Ext. 13114
library.burnley@elht.nhs.uk

Find us
​Staffed Opening Hours
Mon     08:30-16:30
Tue      08:30-16:30
Wed     08:30-16:30
Thu      08:30-16:30
Fri        08:30-16:00
24/7 access to both libraries is available - please see library staff
View our Quality Standards and Performance
Picture
Picture
  • Home
  • Meet the Team
  • Library Facilities
  • Library News
  • FAQS